CureVac | Page 2 | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Tuesday
June 03, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
TUESDAY, JUNE 03, 2025

CureVac

File Photo
Coronavirus chronicle

EU to okay deal with CureVac for supply of up to 405 million Covid vaccines

FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany July 31, 2018. REUTERS/Ralph Orlowski
Coronavirus chronicle

Germany grants BioNTech, CureVac $745 mln to speed up Covid-19 vaccine work

Representational Image. Photo: Reuters
Coronavirus chronicle

Curevac gets 252 mln euro German grant for Covid-19 vaccine

Representational Image. Photo: Reuters
Coronavirus chronicle

EU, CureVac in talks on 225 million doses of potential Covid-19 vaccine

Representational Image. Photo: Reuters
Coronavirus chronicle

CureVac doesn't rule out accelerated approval for Covid-19 vaccine

Representational Image. Photo: Reuters
Global Economy

German Covid-19 vaccine developer looks to raise up to $213 mln in US IPO

Photo: Collected
Global Economy

GSK buys 10% of CureVac in vaccine tech deal

Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken taken April 10, 2020/ Reuters
Coronavirus chronicle

EU in talks with Moderna, BioNtech, CureVac to secure possible Covid vaccines - sources

FILE PHOTO: A vaccination against the coronavirus disease (Covid-19) from German biotechnology company CureVac is ready to use at the start of a clinical test series in the tropical institute of the university clinic in Tuebingen, Germany, June 22, 2020. REUTERS/Kai Pfaffenbach
Coronavirus chronicle

Tesla to make molecule printers for German Covid-19 vaccine developer CureVac

Representational Image. Photo: Reuters
Coronavirus chronicle

Coronavirus vaccine could be on market in mid-2021 - CureVac

Representational Image. Photo: Reuters
Coronavirus chronicle

Germany's CureVac to launch human trial of experimental coronavirus vaccine

FILE PHOTO: Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (Covid-19) disease at a laboratory in Tuebingen, Germany, March 12, 2020. REUTERS/Andreas Gebert
Global Economy

Coronavirus vaccine maker CureVac plans US listing in July

Representational Image. Photo: Reuters
World+Biz

Germany to buy stake in CureVac as world races for Covid-19 vaccine

  • Show More
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net